Combined Immunodeficiency Due to MALT1 Deficiency (IMD12): A Comprehensive Disease Characterization

Disease: Combined Immunodeficiency Due to MALT1 Deficiency MONDO ID: MONDO:0014197 | OMIM: #615468 (Immunodeficiency-12, IMD12) | Gene: MALT1 (HGNC:6819; OMIM 604860) Category:* Mendelian (autosomal recessive inborn error of immunity)

Summary

Combined immunodeficiency due to MALT1 deficiency, also designated Immunodeficiency-12 (IMD12; OMIM #615468; MONDO:0014197), is an ultra-rare autosomal recessive inborn error of immunity caused by biallelic loss-of-function variants in MALT1. MALT1 (mucosa-associated lymphoid tissue lymphoma translocation protein 1) is the only human paracaspase and serves as a core subunit of the CARD11–BCL10–MALT1 (CBM) signalosome, the molecular hub that couples antigen-receptor engagement on T and B lymphocytes to canonical NF-κB activation. When MALT1 function is lost, the CBM complex can no longer transmit antigen-receptor signals to the threshold required for effective lymphocyte activation, producing a disease that combines features of classical immunodeficiency (recurrent infection, poor antibody responses) with immune dysregulation (eczema, elevated IgE, eosinophilia, autoimmunity) — a duality that stems directly from MALT1's dual role in both effector-lymphocyte activation and regulatory T-cell (Treg) homeostasis.

Clinically, affected infants present in the first weeks to months of life (mean onset ~1.6 months) with recurrent bacterial, viral, and fungal infections (100%), skin involvement/eczema (100%), failure to thrive (100%), oral lesions (67%), chronic diarrhea (56%), and autoimmunity (44%). The characteristic laboratory signature includes eosinophilia (~67%), elevated IgE (~22%), typically normal T and NK cell counts but reduced B cells (89% of patients), arrest of B-cell maturation, and impaired specific antibody responses. The disorder is heavily enriched in consanguineous Middle Eastern, Turkish, and North African populations, consistent with a consanguinity/founder effect rather than a single global founder allele, and fewer than ~20 patients had been comprehensively characterized as of 2022.

The prognosis is poor with conservative management: immunoglobulin replacement and antimicrobial prophylaxis are largely ineffective, and infection-related mortality is high (5 of 9 patients died in the largest cohort). Allogeneic hematopoietic stem cell transplantation (HSCT) — which reconstitutes CBM-competent hematopoietic cells — is the only established curative therapy. MALT1 deficiency sits within the broader family of "CBM-opathies" (inborn errors of CARD11, BCL10, and MALT1), and its eczema/high-IgE/sinopulmonary-infection phenotype overlaps with DOCK8 deficiency and hyper-IgE syndromes, so molecular confirmation is required for diagnosis.

1. Disease Information

MALT1 deficiency is an autosomal recessive combined immunodeficiency (CID) with early-onset multisystem disease. It is formally classified as Immunodeficiency-12 with susceptibility to viral, bacterial, and fungal infections (IMD12).

Key identifiers:

Synonyms / alternative names: Immunodeficiency-12; IMD12; MALT1 deficiency; MALT1 paracaspase deficiency; combined immunodeficiency due to MALT1 deficiency; CBM-opathy (MALT1 type).

Information source: The disease-level characterization derives from aggregated case series and individual case reports in the primary literature (e.g., the 19-patient synthesis in PMID: 35079916), supplemented by mechanistic studies in cell lines and model organisms. Given extreme rarity, there are no EHR-scale or registry-scale datasets; all clinical data are individual-patient-derived and then aggregated.

2. Etiology

Primary cause — genetic: The disease is caused by biallelic (homozygous or compound heterozygous) loss-of-function variants in MALT1. In consanguineous families the variants are typically homozygous. There is no environmental or infectious cause of the underlying disorder; infections are the consequence of the immune defect, not its cause.

Genetic risk factors: The sole causal factor is biallelic MALT1 LOF. Consanguinity is the dominant population-level risk factor, as it dramatically increases the probability of homozygosity for rare recessive alleles. No modifier genes have been formally validated, though the broader severity of CBM-opathies depends on which component and residual protein function is affected.

Environmental / lifestyle risk factors: None established as causal. Pathogen exposure determines the pattern and timing of clinical infection but does not cause the immunodeficiency.

Protective factors: Heterozygous carriers are asymptomatic (one functional allele suffices). No protective modifier alleles have been described. The only "protective" intervention is definitive immune reconstitution via HSCT.

Gene–environment interactions: The genetic lesion sets a lowered threshold for immune failure; environmental pathogen load then determines clinical expression (severity/frequency of infections, triggering of eczema flares). This is a "genotype sets susceptibility, environment determines manifestation" relationship rather than a true molecular GxE interaction.

3. Phenotypes

Phenotype frequencies are drawn primarily from the largest cohort (9 new + 10 previously reported patients, n=19; PMID: 35079916).

The phenotype frequencies come directly from the largest reported cohort (PMID: 35079916): "The main clinical findings of the disease were recurrent infections (100%), skin involvement (100%), failure to thrive (100%), oral lesions (67%), chronic diarrhea (56%), and autoimmunity (44%)."

Phenotype characteristics: - Age of onset: Neonatal / early infancy — mean disease onset 1.6 ± 0.7 months (PMID: 35079916): "The mean age of patients and disease onset were 33 ± 17 and 1.6 ± 0.7 months, respectively." - Severity: Severe; life-threatening. - Progression: Progressive without curative treatment; chronic/lifelong course punctuated by acute infectious episodes. - Immunophenotype: "The majority of patients had normal T and NK cells, while eight (89%) exhibited reduced B cells." (PMID: 35079916)

Quality of life impact: Severe. Recurrent infections, chronic diarrhea/enteropathy, failure to thrive, and dermatitis substantially impair growth, nutrition, and daily function in infancy; the burden of hospitalization and the need for HSCT are profound. Formal QoL instrument data (EQ-5D, SF-36) are not available for this ultra-rare disorder.

4. Genetic / Molecular Information

Causal gene: MALT1 (HGNC:6819; chromosome 18q21.32; OMIM 604860). The gene encodes an 824-amino-acid paracaspase* — the only paracaspase in humans.

Protein architecture (relevant to loss-of-function mechanism): - N-terminal death domain - Two N-terminal Ig-like (immunoglobulin-like) domains (Ig1–Ig2; mediate BCL10 binding and oligomerization) - Central caspase-like (paracaspase) protease domain - C-terminal Ig-like domain

Crystallography (1.75 Å) shows the paracaspase domain adopts a fold nearly identical to classic caspases and homodimerizes to form an active protease that cleaves substrates after arginine residues (PMID: 22158899): "The paracaspase domain adopts a fold that is nearly identical to that of classic caspases and homodimerizes similarly to form an active protease." The tandem Ig-like domains additionally mediate oligomerization important for signaling (PMID: 21966355).

Reported pathogenic variants (all germline, biallelic, loss-of-function):

Supporting quotes: - "The patient carried a novel pathogenic biallelic loss-of-function variant in MALT1 (c.1411G > A; p.D471N) located in the caspase-like domain, leading to severely reduced MALT1 protein expression." (PMID: 40748513) - "Next-generation sequencing revealed a novel homozygous variant in the MALT1 gene (c.762dup in exon 5 of 17; p.Ile255TyrfsTer10); this variant is likely pathogenic, thus supporting the genetic diagnosis of immunodeficiency-12 (IMD12)." (PMID: 39017781) - "the MALT1 K543R and M732T variants attenuated MALT1's enzymatic activity and compromised its protein stability" (PMID: 41882201)

Variant classification: Pathogenic / likely pathogenic per ACMG/AMP, supported by functional assays demonstrating reduced protein and/or reduced protease/scaffold activity.

Variant types: Missense, frameshift, and nonsense have all been reported. Functional consequence = loss of function (reduced protein stability and/or reduced protease and scaffold activity).

Allele frequency: Pathogenic MALT1 LOF alleles are essentially absent in the homozygous state in gnomAD, consistent with recessive severe disease.

Somatic vs germline: Disease-causing variants are germline. (Note: MALT1 is also oncogenically activated in lymphoma via the somatic t(11;18) API2-MALT1 fusion and chronic CBM activation — a distinct, unrelated pathology.)

Modifier genes / epigenetics / chromosomal abnormalities: No validated modifier genes, disease-specific epigenetic signatures, or large-scale chromosomal abnormalities are described for the Mendelian deficiency.

5. Environmental Information

Environmental factors: No toxic, radiation, or occupational exposures contribute to this monogenic disease.

Lifestyle factors: Not applicable (disease of infancy).

Infectious agents: Pathogens are downstream consequences, not causes. The combined immunodeficiency predisposes to recurrent bacterial, viral, and fungal infections. Staphylococcal skin/soft-tissue infections and mucocutaneous candidiasis are notable, overlapping with the DOCK8/hyper-IgE differential (PMID: 39017781). Chronic mucocutaneous candidiasis-type and other opportunistic infections reflect the combined T/B defect.

6. Mechanism / Pathophysiology

Ordered causal chain

1. Biallelic loss-of-function variants in MALT1 (missense/frameshift/nonsense) lead to severely reduced MALT1 protein and/or loss of paracaspase protease and scaffold activity.
2. Loss of functional MALT1 results in a non-functional or crippled CARD11–BCL10–MALT1 (CBM) signalosome, which normally assembles downstream of the T-cell receptor (TCR) and B-cell receptor (BCR).
3. A defective CBM complex fails to transmit antigen-receptor signals to the threshold required for canonical NF-κB activation (demonstrated by reduced p65/RelA phosphorylation).
4. Impaired NF-κB signaling branches into two consequences:
5. (Branch A — effector/immunodeficiency): reduced lymphocyte activation, proliferation, and cytokine output (deficient IL-2 and TNF-α), leading to impaired T-cell help, arrest of B-cell maturation at the transitional/naïve stage, reduced memory and total B cells, and poor specific antibody responses → recurrent infections and (functional) agammaglobulinemia.
6. (Branch B — regulatory/dysregulation): loss of MALT1 protease activity results in reduced regulatory T-cell (Treg) and follicular regulatory (Tfr) cell numbers and function, plus Th2 skewing, leading to autoimmunity, eczema/atopic dermatitis, eosinophilia, and elevated IgE.
7. The combined effector failure plus immune dysregulation manifests clinically as early-infancy combined immunodeficiency with infections, enteropathy, failure to thrive, dermatitis, and autoimmunity.

(The branching in step 4 is directly inferred from the dual scaffold/protease biochemistry of MALT1 and is demonstrated in both patient cells and model organisms; see below.)

Molecular and cellular detail

Molecular pathway (central): The CBM signalosome bridges ITAM-coupled antigen receptors (TCR/BCR) to NF-κB, and also to JNK and mTORC1 (PMID: 30283440). MALT1 integrates receptor-derived signals and "determines whether downstream nuclear factor kappa B (NF-κB) activation reaches thresholds required for effective immune responses" (PMID: 42745540): "As a central component of the CARD11-BCL10-MALT1 (CBM) signalosome, MALT1 integrates receptor-derived signals and determines whether downstream nuclear factor kappa B (NF-kB) activation reaches thresholds required for effective immune responses."

Dual function of MALT1 (PMID: 37126937): "MALT1 acts as a scaffolding protein to drive activation of NF-κB transcription factors and as a protease to modulate signaling and immune activation by cleavage of distinct substrates." - Scaffold function: nucleates IKK activation → NF-κB. - Protease function: cleaves negative regulators of NF-κB (A20, CYLD, RelB) and RNA-binding repressors (Regnase-1, Roquin), thereby sustaining lymphocyte proliferation/survival and shaping cytokine mRNA stability.

Patient-level evidence: A p.D471N LOF variant "Impaired CBM-mediated NF-κB activation was confirmed by reduced phosphorylation of the p65 subunit, resulting in deficient production of IL-2 and TNF-α" and "This functional defect caused lower Tfr and Treg cells, a normal proportion of Tfh cells, with higher expression of activation markers PD-1 and ICOS" (PMID: 40748513). B-cell maturation arrest with elevated IgE and otherwise normal subset counts has been documented (PMID: 39017781): "He had elevated serum IgE and normal B- and T-lymphocyte subset counts, but there was an arrest in the B-cell maturation."

Treg dependence on MALT1 protease — mechanistic link (model organisms): MALT1 protease activity in Tregs drives TCR-induced upregulation of MYC, supporting mitochondrial function and homeostatic Treg expansion (PMID: 34668583): "MALT1 protease activity controls the TCR-induced upregulation of the transcription factor MYC and the subsequent expression of MYC target genes in Tregs." Thus the dysregulation branch is tied specifically to protease (not scaffold) function.

Cell types involved (suggested CL terms): CD4+ T cell (CL:0000624), CD8+ T cell (CL:0000625), regulatory T cell (CL:0000815), follicular regulatory T cell, B cell (CL:0000236), naïve/transitional B cell, memory B cell (CL:0000787), NK cell (CL:0000623), myeloid dendritic cell.

Suggested GO terms: antigen receptor-mediated signaling pathway (GO:0050851), I-κB kinase/NF-κB signaling (GO:0007249), positive regulation of NF-κB transcription factor activity (GO:0051092), T cell receptor signaling pathway (GO:0050852), B cell receptor signaling pathway (GO:0050853), regulatory T cell differentiation (GO:0045066), proteolysis (GO:0006508), cysteine-type endopeptidase activity (GO:0004197).

Subcellular compartments (GO Cellular Component): cytoplasm/cytosol (GO:0005829) where the CBM signalosome assembles; the signal terminates in the nucleus (GO:0005634) via NF-κB nuclear translocation.

Immune system involvement: Combined (T + B) immunodeficiency plus immune dysregulation (autoimmunity, atopy). This is the defining pathophysiology.

7. Anatomical Structures Affected

Organ / system level: - Immune/lymphoreticular system (UBERON:0002405 immune system; UBERON:0000029 lymph node; UBERON:0002106 spleen; UBERON:0002370 thymus) — primary. - Skin (UBERON:0002097) — eczema/dermatitis, staphylococcal infection. - Gastrointestinal tract (UBERON:0001555 digestive tract) — chronic diarrhea/enteropathy. - Oral cavity / mucosa (UBERON:0000167) — oral lesions, candidiasis. - Respiratory tract (UBERON:0000065) — recurrent sinopulmonary infection. - Systemic: failure to thrive reflects multi-organ nutritional/growth impact.

Tissue and cell level: Lymphoid tissue and peripheral blood leukocytes. Affected cell populations: T cells (including Tregs and Tfr), B cells (maturation arrest at transitional/naïve stage; reduced memory B cells), NK cells (numerically normal but functionally impaired), and myeloid dendritic cells.

Subcellular level: Cytoplasmic CBM signalosome assembly (GO:0005829); nuclear NF-κB-driven transcription (GO:0005634).

Localization / lateralization: Systemic and bilateral/diffuse (not a focal or lateralized disease).

8. Temporal Development

• Onset: Congenital genetic defect with clinical onset in the neonatal period / early infancy (mean 1.6 ± 0.7 months; PMID: 35079916). Onset pattern is early and progressive.
• Progression: Progressive and life-threatening without immune reconstitution; chronic/lifelong. Clinical course is punctuated by acute infectious episodes superimposed on chronic enteropathy, dermatitis, and failure to thrive.
• Disease course pattern: Chronic-progressive with episodic infectious exacerbations.
• Remission: No spontaneous remission. Durable remission/cure is achieved only through allogeneic HSCT.
• Critical period / intervention window: Early infancy — prompt molecular diagnosis and HSCT before irreversible infectious/organ damage is the key window of opportunity.

9. Inheritance and Population

Inheritance: Autosomal recessive. Affected individuals are homozygous (consanguineous families) or compound heterozygous for MALT1 LOF variants; heterozygous carriers are asymptomatic.

Epidemiology: Ultra-rare. Only ~19 patients had been comprehensively characterized by 2022 (9 new + 10 previously reported; PMID: 35079916): "We also analyzed ten previously reported patients to comprehensively evaluate genotype/phenotype correlation." Additional single case reports have appeared since (Egyptian, Chinese patients). Orphanet lists prevalence as <1/1,000,000. No validated incidence figures exist.

Penetrance / expressivity: Biallelic LOF appears highly penetrant for combined immunodeficiency; expressivity is somewhat variable in the balance of immunodeficiency vs. dysregulation features and in residual B/T function, likely reflecting variant-specific residual activity (hypomorphic vs. null).

Founder effects / consanguinity: Reported families are frequently consanguineous with homozygous variants, heavily weighted toward Middle Eastern/Turkish and North African populations — consistent with a consanguinity/founder effect rather than a single global founder allele (PMID: 39017781: "Next-generation sequencing revealed a novel homozygous variant in the MALT1 gene").

Carrier frequency: Not formally established; pathogenic LOF alleles are essentially absent in the homozygous state in gnomAD.

Sex ratio / age distribution: Both sexes affected (autosomal). Affected individuals are infants/young children.

10. Diagnostics

Clinical / laboratory tests: - Immunophenotyping (flow cytometry): typically normal T and NK cell counts; reduced B cells (89%); reduced memory B cells; arrest of B-cell maturation; reduced Treg/Tfr; elevated activation markers (PD-1, ICOS). - Immunoglobulins: impaired specific antibody responses; may trend toward hypogammaglobulinemia/agammaglobulinemia; elevated IgE in a subset (~22%). - CBC: eosinophilia (~67%). - Functional assays: reduced lymphocyte proliferation to anti-CD3; reduced NF-κB activation (↓phospho-p65) on PMA/ionomycin or receptor stimulation; deficient IL-2/TNF-α production. These functional readouts are central to confirming pathogenicity.

Genetic testing (definitive): Molecular confirmation is required because the clinical picture overlaps with other CBM-opathies, DOCK8 deficiency, and hyper-IgE syndromes. - Whole-exome / whole-genome sequencing (WES/WGS) is the preferred first-line approach, especially given phenotypic overlap; upfront genomic sequencing shortens time to diagnosis in primary atopic disorders (PMID: 39381601). - Targeted inborn-errors-of-immunity (IEI)/SCID/CID gene panels including MALT1, CARD11, BCL10, CARD9, DOCK8. - Single-gene MALT1 sequencing confirmed by Sanger; functional validation of variant impact strengthens classification.

Clinical criteria / differential diagnosis: No disease-specific consensus criteria exist; diagnosis rests on the combined immunodeficiency phenotype plus biallelic MALT1 LOF with functional corroboration. Differential diagnoses to exclude: DOCK8 deficiency, hyper-IgE syndromes, other SCID/CID, BCL10 and CARD11 deficiencies (other CBM-opathies), IPEX, Omenn syndrome, and Wiskott-Aldrich syndrome. "Although the presence of eczema, recurrent sinopulmonary, and staphylococcal infections are suggestive of DOCK8 deficiency, they are also a finding in CARD11 and MALT1 deficiency." (PMID: 39017781). BCL10 deficiency shares an overlapping immunophenotype (PMID: 34868072: "this patient displays a reduction in NK, γδT, Tregs, and T").

Screening: No population newborn screening specifically detects MALT1 deficiency; notably, SCID TREC-based newborn screening may be normal because T-cell numbers are often preserved — an important caveat. Cascade/carrier testing in affected consanguineous families is valuable.

11. Outcome / Prognosis

Survival / mortality: Poor without curative therapy. In the largest cohort, "Immunoglobulin replacement and antibiotics prophylaxis were mostly ineffective in reducing the frequency of infections and other complications. One patient received hematopoietic stem cell transplantation (HSCT) and five patients died as a complication of life-threatening infections." (PMID: 35079916). The p.D471N patient experienced early death (PMID: 40748513).

Morbidity: High — recurrent severe infections, chronic enteropathy, failure to thrive, dermatitis, and autoimmune complications.

Disease-specific complications: Life-threatening bacterial/viral/fungal infections (leading cause of death), enteropathy with malnutrition, autoimmune manifestations.

Recovery potential: Minimal with supportive care alone; curative potential exists with successful allogeneic HSCT (reconstitutes CBM-competent hematopoietic cells).

Prognostic factors: Timing of diagnosis and access to HSCT; infection burden and organ damage at presentation; likely residual MALT1 function (hypomorphic vs. null variant).

12. Treatment

Supportive / pharmacotherapy (largely palliative): - Immunoglobulin replacement (IVIG/SCIG) — NCIT: Intravenous Immunoglobulin Therapy. Largely ineffective at preventing infections in this disease. - Antimicrobial / antifungal / antiviral prophylaxis. Mostly ineffective at reducing complications. - Management of enteropathy and dermatitis — nutritional support, topical/skin care.

Supporting evidence: "Immunoglobulin replacement and antibiotics prophylaxis were mostly ineffective in reducing the frequency of infections and other complications." (PMID: 35079916).

Curative / advanced therapeutics: - Allogeneic hematopoietic stem cell transplantation (HSCT) — NCIT: Allogeneic Hematopoietic Stem Cell Transplantation (C15431). The only established curative therapy; reconstitutes CBM-competent lymphocytes. Reported in only a minority of patients to date; early transplantation before severe infectious damage is the goal. - Gene therapy / gene editing: Not yet available; conceptually attractive given the monogenic, hematopoietic-restricted nature of the defect — a plausible future direction but no clinical programs reported.

Pharmacologic caution — MALT1 inhibitors: MALT1 protease inhibitors are in development for lymphoma and autoimmune disease. Importantly, pharmacological MALT1 inhibition reproduces an IPEX-like, Treg-depleting autoimmune pathology in animal models (PMID: 32425939): "pharmacological inhibition of MALT1 was associated with a rapid and dose-dependent reduction in Tregs and resulted in the progressive appearance of immune abnormalities and clinical signs of an IPEX-like pathology." This underscores that reducing MALT1 function is deleterious — relevant both to understanding the patient phenotype and to avoiding iatrogenic harm.

Treatment outcomes / strategy: No formal treatment algorithms exist for this ultra-rare disease; management mirrors severe combined/combined immunodeficiency protocols (prophylaxis + definitive HSCT). Genotype-guided prognostication (null vs. hypomorphic) may refine urgency.

13. Prevention

• Primary prevention: Not possible for the monogenic disease itself. Genetic counseling for consanguineous families and carrier couples is the principal preventive measure; preimplantation genetic diagnosis (PGD) and prenatal testing are options when the familial variant is known.
• Secondary prevention: Early molecular diagnosis enables timely HSCT before irreversible infectious/organ damage. Cascade screening of at-risk relatives in affected families.
• Tertiary prevention: Infection prophylaxis, nutritional support, and vigilant management of autoimmune/atopic complications pending definitive therapy.
• Immunization caveat: As in other combined immunodeficiencies, live vaccines are contraindicated; vaccine responses are typically poor.
• Public health: Awareness of consanguinity-associated recessive IEI and incorporation of MALT1 into IEI gene panels improve detection.

14. Other Species / Natural Disease

Taxonomy / orthologs: MALT1 is evolutionarily conserved in mammals. Mouse Malt1 (NCBI Gene) is the principal ortholog used in disease modeling.

Natural disease in animals: No naturally occurring MALT1-deficiency disease is established in companion animals or wildlife (no prominent OMIA entry). However, pharmacological MALT1 protease inhibition in rats and dogs produces a progressive IPEX-like pathology with severe Treg reduction (PMID: 32425939), demonstrating cross-species conservation of the Treg-dependent dysregulation mechanism.

Comparative biology: The scaffold/protease duality and CBM–NF-κB axis are conserved across mammals, making mouse models highly informative. Zoonotic potential: Not applicable (non-infectious genetic disease).

15. Model Organisms

Mouse models are the principal system and recapitulate the immunodeficiency–dysregulation duality:

Supporting quotes: - "here we report that MALT1-deficient mice develop atopic-like dermatitis upon aging, which is preceded by Th2 skewing, an increase in serum IgE, and a decrease in Treg frequency and surface expression of the Treg functionality marker CTLA-4." (PMID: 31632405) - "MALT1 protease activity controls the TCR-induced upregulation of the transcription factor MYC and the subsequent expression of MYC target genes in Tregs" (PMID: 34668583)

Phenotype recapitulation: Strong for the atopy/Th2/IgE/Treg-loss axis (dysregulation branch). Limitations: Complete-knockout mice emphasize dysregulation/atopy; the severe early-infancy infectious mortality seen in humans is less fully modeled, and the separation of scaffold vs. protease contributions (via protease-dead knock-ins) does not perfectly mirror human null/hypomorphic variants. Model databases: MGI, IMPC, IMSR.

Mechanistic Model (Synthesis)

   Biallelic LOF MALT1 variants (missense / frameshift / nonsense)
                         │  (↓ protein, ↓ protease + scaffold)
                         ▼
        Non-functional CARD11–BCL10–MALT1 (CBM) signalosome
                         │  downstream of TCR / BCR
                         ▼
     Antigen-receptor signal fails to reach NF-κB activation threshold
                 (↓ phospho-p65; also ↓ JNK, ↓ mTORC1)
                         │
         ┌───────────────┴────────────────┐
         ▼                                 ▼
  BRANCH A: EFFECTOR FAILURE         BRANCH B: REGULATORY FAILURE
  (loss of scaffold + protease)      (loss of protease → ↓MYC in Tregs)
  • ↓ IL-2, ↓ TNF-α                   • ↓ Treg / ↓ Tfr
  • B-cell maturation arrest          • Th2 skewing
  • ↓ memory & total B cells          • ↑ IgE, eosinophilia
  • poor antibody responses           • ↑ PD-1 / ICOS activation
         │                                 │
         ▼                                 ▼
  Recurrent infections,              Eczema/dermatitis,
  functional agammaglobulinemia      autoimmunity
         └───────────────┬────────────────┘
                         ▼
   Early-infancy COMBINED IMMUNODEFICIENCY + IMMUNE DYSREGULATION
   (infections, enteropathy, failure to thrive, oral lesions)
                         │
                         ▼
          Poor prognosis → curative only by allogeneic HSCT

The key unifying insight is that MALT1's two biochemical activities map onto the two clinical faces of the disease: scaffold-driven NF-κB loss drives effector/immunodeficiency features, while protease loss (via the MYC–mitochondrial axis in Tregs) drives the regulatory/dysregulation features. This is corroborated in patients (↓NF-κB, ↓IL-2/TNF-α, ↓Treg/Tfr) and in model organisms (protease-dead knock-ins → Treg-dependent autoimmunity; pharmacologic inhibition → IPEX-like pathology).

Evidence Base

Evidence source types: Human clinical (cohorts/case reports: 35079916, 40748513, 39017781, 41882201, 34868072); in vitro/structural (22158899, 21966355, 37126937); model organism (31632405, 34668583, 32425939).

Limitations and Knowledge Gaps

1. Extreme rarity (n≈19 + scattered case reports). All epidemiology is case-derived; no validated prevalence/incidence, penetrance, or expressivity estimates. Phenotype frequencies may be biased by ascertainment toward severe/consanguineous cases.
2. Genotype–phenotype correlation is incompletely resolved. The spectrum of variant types (null vs. hypomorphic) and how residual activity modulates the immunodeficiency-vs-dysregulation balance remain under-characterized.
3. HSCT outcome data are sparse — only a minority of reported patients were transplanted; optimal conditioning, timing, and long-term outcomes are not established.
4. Human mechanistic data are limited to a few patients; much of the protease-vs-scaffold dissection relies on model organisms and pharmacology, which may not perfectly mirror human null/hypomorphic variants.
5. No disease-specific QoL, biomarker-based prognostic, or newborn-screening data. Standard SCID TREC screening may miss MALT1 deficiency because T-cell numbers are often preserved.
6. No gene therapy programs or formal treatment algorithms exist.

Proposed Follow-up Experiments / Actions

1. Establish an international MALT1-deficiency patient registry to aggregate genotype, immunophenotype, treatment, and HSCT outcome data and derive robust natural-history and genotype–phenotype correlations.
2. Systematic functional classification of MALT1 variants (NF-κB reporter, protease-cleavage, protein-stability assays) to build an ACMG-aligned variant interpretation resource distinguishing null vs. hypomorphic alleles.
3. Define HSCT best practices (timing, conditioning, donor source) through multicenter outcome analysis, and evaluate whether early transplantation (before severe infection) improves survival.
4. Single-cell transcriptomic/immune profiling of patient PBMCs to map, at cell-type resolution, the effector vs. regulatory lesions (B-cell maturation block, Treg/Tfr deficits) and identify candidate biomarkers.
5. Preclinical evaluation of gene correction (lentiviral MALT1 addition or base/prime editing in patient HSPCs) given the monogenic, hematopoietic-restricted nature of the defect.
6. Incorporate MALT1 into standard IEI/SCID gene panels and raise clinician awareness of the DOCK8/hyper-IgE phenotypic overlap and the SCID-screening blind spot (preserved T cells).

Report compiled from autonomous multi-iteration literature synthesis (8 confirmed findings, 25 papers reviewed). All clinical and mechanistic claims are attributed to the cited primary literature by PMID.